T. Rowe Price Associates
SYRE icon

T. Rowe Price Associates’s Spyre Therapeutics SYRE Stock Holding History

T. Rowe Price Associates’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263M Buy
2,960,855
+1,362,125
+85% +$99.4M 0.03% 438
2026
Q1 		$80.6M Sell
1,598,730
-3,152
-0.2% -$119K 0.01% 655
2025
Q4 		$52.5M Buy
1,601,882
+981,262
+158% +$25.6M 0.01% 807
2025
Q3 		$10.4M Sell
620,620
-309,861
-33% -$5.05M ﹤0.01% 1219
2025
Q2 		$13.9M Buy
930,481
+681,939
+274% +$10.1M ﹤0.01% 1050
2025
Q1 		$4.01M Sell
248,542
-257,908
-51% -$5.37M ﹤0.01% 1315
2024
Q4 		$11.8M Buy
506,450
+77,323
+18% +$2.27M ﹤0.01% 1121
2024
Q3 		$12.6M Buy
429,127
+121,151
+39% +$3.37M ﹤0.01% 1100
2024
Q2 		$7.24M Buy
307,976
+229,447
+292% +$7.74M ﹤0.01% 1154
2024
Q1 		$2.98M Buy
+78,529
New +$2.28M ﹤0.01% 1389

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's SYRE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Spyre Therapeutics (SYRE) stake by 85% in Q2 2026, buying an estimated $99.4M and bringing the position to 2,960,855 shares worth $263M. The position accounts for 0.03% of the portfolio, ranked #438.

T. Rowe Price Associates first reported a position in SYRE in Q1 2024 and has held it in 10 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • T. Rowe Price Associates held 2,960,855 shares of Spyre Therapeutics worth $263M as of Q2 2026.
  • T. Rowe Price Associates bought 1,362,125 Spyre Therapeutics shares in Q2 2026, an estimated $99.4M.
  • Spyre Therapeutics made up 0.03% of T. Rowe Price Associates's portfolio in Q2 2026, its #438 holding.
  • T. Rowe Price Associates first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.